SGLT2-remmers en diabetische ketoacidoses
- 15 April 2015
- journal article
- internationaal onderzoek
- Published by Springer Nature in Nederlands Tijdschrift voor Diabetologie
- Vol. 14 (1) , 10-13
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 DiabetesNew England Journal of Medicine, 2015
- Euglycemic Diabetic Ketoacidosis: A Predictable, Detectable, and Preventable Safety Concern With SGLT2 InhibitorsDiabetes Care, 2015
- Current State of Type 1 Diabetes Treatment in the U.S.: Updated Data From the T1D Exchange Clinic RegistryDiabetes Care, 2015
- Exploring the Potential of the SGLT2 Inhibitor Dapagliflozin in Type 1 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Pilot StudyDiabetes Care, 2014
- SGLT inhibition in patients with type 1 diabetesThe Lancet Diabetes & Endocrinology, 2014
- SGLT2 inhibitors in the treatment of type 2 diabetesDiabetes Research and Clinical Practice, 2014
- Sodium-Glucose Cotransporter 2 Inhibition and Glycemic Control in Type 1 Diabetes: Results of an 8-Week Open-Label Proof-of-Concept TrialDiabetes Care, 2014
- Hyperglycemic Crises in Adult Patients With DiabetesDiabetes Care, 2009
- Euglycemic diabetic ketoacidosis.BMJ, 1973
- Euglycaemic Diabetic KetoacidosisBMJ, 1973